• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    2/12/24 5:27:29 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    SC 13G/A 1 enovis_sc13ga-123123.htm AMENDMENT TO SC 13G

     

     

     

    UNITED STATES

     SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     ______________

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Enovis Corporation

    (Name of Issuer)

     

    Common Stock, $0.001 per share

    (Title of Class of Securities)

     

    194014502

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 194014502

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Durable Capital Partners LP

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ☐

    (b)       ☐

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER
    OF
    5

    SOLE VOTING POWER

     

    0 

    SHARES

    BENEFICIALLY

     OWNED BY

    6

    SHARED VOTING POWER

     

    0        

    EACH

    REPORTING

     PERSON 

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0% 

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN 

           

     

     

     

    Item 1(a).Name of Issuer:

     

    Enovis Corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    2711 Centerville Road, Suite 400

    Wilmington, DE 19808

     

    Item 2(a).Names of Person Filing:

     

    The name of the person filing this report is:

    Durable Capital Partners LP (the “Reporting Person”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of the Reporting Person is:

    4747 Bethesda Avenue, Suite 1002

     Bethesda, Maryland 20814

     

    Item 2(c).Citizenship or Place of Organization:

     

    The Reporting Person is a limited partnership organized under the laws of the State of Delaware.

     

    Item 2(d).Title of Class of Securities:

     

    Common stock, $0.001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    194014502

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)☒ An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

     

     

     

    (g)☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

     

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)☐ A non-U.S. institution that is the functional equivalent of any of the institutions listed in § 240.13d-1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institution.

     

    (k)☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    Item 4.Ownership.

     

    The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G.

     

    The Reporting Person, as the investment adviser to Durable Capital Master Fund LP, has sole power to direct the vote and disposition of Common Stock (the “Shares”). Durable Capital Partners GP LLC (“Durable GP”) is the general partner of the Reporting Person, and Henry Ellenbogen is the chief investment officer of the Reporting Person and the managing member of Durable GP.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    See disclosure of relationships among parties under Item 4. The economic benefits of the Shares are shared based on agreements among the parties.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    See control and Shares holding disclosure in Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Inapplicable.

     

     

     

     

    Item 9.Notice of Dissolution of Group.

     

    Inapplicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:      February 12, 2024

     

    DURABLE CAPITAL PARTNERS LP

     

    By: /s/ Julie Jack  
      Name: Julie Jack  
      Title: Authorized Person  

     

     

    Get the next $ENOV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JP Morgan initiated coverage on Enovis Corporation with a new price target

    JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

    6/13/24 7:06:52 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Stephens initiated coverage on Enovis Corporation with a new price target

    Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

    2/13/24 6:34:49 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis to Participate in Upcoming Investor Conferences

    Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the live audio webcasts, as well as a replay of these events, will be available on the Company's website under the Investors tab at Events and Presentations. ABOUT

    8/8/25 9:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Second Quarter 2025 Results

    Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

    8/7/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host Second Quarter 2025 Results Conference Call on August 7th

    Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 6

    7/8/25 4:05:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Strategy & Business Dev. Pryor Daniel A bought $289,000 worth of shares (10,000 units at $28.90), increasing direct ownership by 7% to 161,115 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/14/25 4:05:08 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ENOV
    SEC Filings

    View All

    EVP, Strategy & Business Dev. Pryor Daniel A bought $289,000 worth of shares (10,000 units at $28.90), increasing direct ownership by 7% to 161,115 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/14/25 4:05:08 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Principal Accounting Officer Kleckner John covered exercise/tax liability with 173 shares, decreasing direct ownership by 2% to 9,834 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/7/25 9:00:04 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    GROUP PRESIDENT, RECON Vogt Louis covered exercise/tax liability with 460 shares, decreasing direct ownership by 1% to 36,385 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/7/25 9:00:06 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation

    SCHEDULE 13G/A - Enovis CORP (0001420800) (Subject)

    8/14/25 9:02:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation

    SCHEDULE 13G/A - Enovis CORP (0001420800) (Subject)

    8/12/25 12:06:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Enovis Corporation

    10-Q - Enovis CORP (0001420800) (Filer)

    8/7/25 4:26:39 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis Announces Second Quarter 2025 Results

    Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

    8/7/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host Second Quarter 2025 Results Conference Call on August 7th

    Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 6

    7/8/25 4:05:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces First Quarter 2025 Results

    Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

    5/8/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

    WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

    9/9/24 3:50:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care